Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nizofenone is a neuroprotective small molecule drug belonging to the benzophenone class. It protects neurons from death following cerebral anoxia (interruption of oxygen supply to the brain) and has been investigated for use in acute neurological conditions such as stroke, traumatic brain injury, and subarachnoid hemorrhage[1][3][4]. Its mechanism of action includes ameliorating various pathophysiologic events during ischemia—such as ATP depletion, lactate accumulation, glutamate release (notably blocking ischemia-induced excessive glutamate release), free fatty acid liberation, edema, and neuronal degeneration[4][6]. Nizofenone also acts as a radical scavenger comparable to vitamin E and inhibits oxygen radical-induced lipid peroxidation[4][6]. Clinical studies have demonstrated its efficacy in preventing delayed ischemic neurologic deficits due to late vasospasm following subarachnoid hemorrhage[4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nizofenone.